Map inflammation to guide treatment
- Trial ID
- NCT03457493
- Official Title
- UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy
- Goal
- Map inflammation to guide treatment
- Phase
- PHASE1, PHASE2
- Status
- RECRUITING
- Sponsor
- University of Alabama at Birmingham
- Study Type
- INTERVENTIONAL
- Enrollment
- 205 participants
- Conditions
- Parkinson Disease
- Interventions
- DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis
Plain-Language Summary
The goal is to map neuroinflammation in Parkinson's by measuring activated immune cells in the brain that may contribute to disease progression. The approach uses an injected PET tracer, [18F]DPA-714, that binds the TSPO protein on activated microglia, paired with MRI and metabolite analysis to show where and how much inflammation is present; because the tracer is only for imaging it does not change or interact with levodopa or other Parkinson's medications. Adults 30 and older already enrolled in UAB's related Parkinson's immune imaging cohorts are eligible, participants must be a high or mixed TSPO binder based on rs6971 genotyping, and people with MRI/PET contraindications, low-affinity binders, or inability to safely undergo imaging are excluded. For the UDALL 5-year follow-up group you must be a UDALL baseline participant with baseline imaging done within the past 6 years.
Locations
- UAB Advanced Imaging Facility, Birmingham, Alabama, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying DPA-714-PET/MRI. The goal is to map neuroinflammation in Parkinson's by measuring activated immune cells in the brain that may contribute to disease progression. The approach uses an injected PET tracer, [18F]DPA-714, that binds the TSPO protein on activated microglia, paired with MRI and metabolite analysis to show where and how much inflammation is present; because the tracer is only for imaging it does not change or interact with levodopa or other Parkinson's medications. Adults 30 and older already enrolled in UAB's related Parkinson's immune imaging cohorts are eligible, participants must be a high or mixed TSPO binder based on rs6971 genotyping, and people with MRI/PET contraindications, low-affinity binders, or inability to safely undergo imaging are excluded. For the UDALL 5-year follow-up group you must be a UDALL baseline participant with baseline imaging done within the past 6 years.
- Who can participate?
- Participants must be at least 30 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1/Phase 2 trial is estimated to last approximately 9 years and 2 months.